RMN.F : Summary for MEDICINOVA NEW DL-,001 - Yahoo Finance

U.S. Markets closed

MediciNova, Inc. (RMN.F)


Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
5.65-0.04 (-0.65%)
At close: 8:03AM CET
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close5.69
Open5.65
Bid5.59 x 47400
Ask5.82 x 45600
Day's Range5.65 - 5.65
52 Week Range4.97 - 8.33
Volume28
Avg. Volume12
Market Cap199.99M
BetaN/A
PE Ratio (TTM)-17.19
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks Small Cap Research2 months ago

    MNOV: Phase 2b Trial of MN-166 in Progressive MS Will Continue to Conclusion

    On December 19, 2016, MediciNova, Inc. (MNOV) announced that the Data and Safety Monitoring Board (DSMB) for the ongoing Phase 2b clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (MS) reviewed the results of the interim efficacy analysis and recommended to the National Institute of Neurological Diseases and Stroke (NINDS) that the trial should continue as planned, to which the NINDS has agreed. Thus, the fact that the DSMB recommended that the trial continue as planned is indicative that there is at least a positive trend in the direction of efficacy for MN-166. If there was no trend in favor of MN-166, the trial would have been stopped for futility.

  • Zacks Small Cap Research4 months ago

    MNOV: Interim Analysis of MN-166 in Progressive MS in 4Q16; ODD granted to MN-166 for ALS

    MediciNova (MNOV) is developing MN-166 (ibudilast) for the treatment of primary and secondary progressive multiple sclerosis (PPMS and SPMS), amyotrophic lateral sclerosis (ALS), methamphetamine (MA) addiction, opioid dependence, and alcohol dependence. The drug is currently being tested in four separate clinical trials in the aforementioned indications with two trials recently completed in alcohol dependence and opioid dependence. MN-166 was previously tested in a randomized, double blind, placebo controlled Phase 2a clinical trial to evaluate its safety and effectiveness in relapsing MS patients.

  • MNOV: Interim Analysis For Phase 2b Trial of MN-166 in Progressive MS in 4Q16
    Zacks Small Cap Research7 months ago

    MNOV: Interim Analysis For Phase 2b Trial of MN-166 in Progressive MS in 4Q16

    MediciNova (MNOV) is developing MN-166 (ibudilast) for the treatment of primary and secondary progressive multiple sclerosis (PPMS and SPMS), amyotrophic lateral sclerosis (ALS), methamphetamine (MA) addiction, opioid dependence, and alcohol dependence. The drug is currently being tested in four separate clinical trials in the aforementioned indications with two trials recently completed in alcohol dependence and opioid dependence. MN-166 is an anti-inflammatory drug that has been used for over 20 years in Japan to treat asthma (Rolan et al., 2009) and post-stroke dizziness.